Yescarta Reimbursement in Japan Matched to Kymriah’s Latest Price Adjustment; Will Breyanzi be Priced Similarly?
On Wednesday, April 21, Japan’s Ministry of Health, Labor, and Welfare (MHLW) listed Yescarta (Gilead) in the NHI’s reimbursement price list (press release, PharmaJapan, Apr 2021). Below, Celltelligence provides thoughts on Japan’s pricing for Yescarta and Kymriah and how this could impact Breyanzi’s (BMS) reimbursement discussions.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.